Pfizer Quietly Suspends Patient Enrollment for Early Stage Tumor Study

This study has suspended participant recruitment.

Further study details as provided by Pfizer:

Primary Outcome Measures:

* Number of participants with Dose-limiting toxicities (DLT) {Part1} [ Time Frame: Day 1 up to Day 21 ]
* First cycle DLTs in order to determine maximum tolerated dose

Back to news